Local Anesthesia for TAVR Was Safe and Reduced Hospital Stays

A minimalist approach to transcatheter aortic valve replacement (TAVR) involving local anesthesia appears to have several advantages, according to this new meta-analysis.

 

In addition to shortening times for procedures and lengths of stay in the critical care unit and hospital, lighter sedation may lower the need for transfusions or treatment with inotropes or vasopressors.

 

Those benefits do not come with clinical complications. In fact, mortality at 30 days was lower in those receiving TAVR with local anesthesia (3.7% vs. 4.2%; risk ratio [RR]: 0.76; 95% confidence interval [CI]: 0.64-0.92).

 

In the earlier days of TAVR, procedures were typically performed under general anesthesia with orotracheal intubation. However, in time, accumulating evidence suggested that using local anesthesia in the procedure, as part of a minimalist approach, is not only feasible but also beneficial.

 

While the meta-analysis is not to be considered as definitive evidence as regards hard endpoints such as mortality, a minimalist strategy presents enough advantages to support its application.

 

This meta-analysis included 27 studies and a total of 24,085 patients.

 

Most procedural variables turned out to be similar for both strategies, including rates of stroke, acute myocardial infarction, renal failure, vascular complications, major bleeding, a need for a permanent pacemaker, paravalvular insufficiency, or fluoroscopy time.

 

Patients who received local anesthesia presented the following advantages:

  • a shorter average procedure time (90 vs. 127 minutes),
  • less time in the critical care unit (1.5 vs. 3.0 days),
  • less time in the hospital (5 vs 9 days),
  • possibly, lower mortality (although this conclusion might be biased).

 

Original title: Comparison of Local Versus General Anesthesia in Patients Undergoing Transcatheter Aortic Valve Replacement: A Meta-Analysis and Meta-Regression.

Presenter: Villablanca PA.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....